Zenrelia Tablet for Dogs 8.5mg (Single Tablet)

Zenrelia Tablet for Dogs 8.5mg is a specially formulated treatment for dogs suffering from allergic dermatitis. This condition often leads to persistent itching, skin irritation, and discomfort, impacting your dog's quality of life. Zenrelia works to alleviate these symptoms, helping your dog return to a more comfortable, normal state.

Why Choose Zenrelia 8.5mg?

• Once-Daily Dosing: Simplify your pet's medication routine with a single daily dose, making it easier to manage long-term treatment.
• Hypoallergenic and Flavouring-Free: These tablets are designed to be hypoallergenic and free from flavourings, reducing the risk of triggering food allergies in sensitive dogs.
• Clinically Proven Effectiveness: Studies show Zenrelia can significantly improve the condition of itchy dogs, helping a large percentage return to a normal itch score, even when used for long-term maintenance therapy.
• Trusted Treatment: Zenrelia is well-tolerated and provides targeted relief, helping to manage the frustrating symptoms of allergic dermatitis so your dog can enjoy life more fully.

As a prescription-only medicine, Zenrelia Tablet for Dogs 8.5mg ensures your pet receives appropriate care under veterinary guidance. Always consult your veterinarian to determine if this is the right treatment for your dog's specific needs.

Always administer Zenrelia Tablet for Dogs 8.5 mg exactly as prescribed by your veterinary surgeon. The dosage is based on your dog's body weight and should be given once daily, with or without food.

The recommended dose is 0.6-0.8 mg ilunocitinib per kg body weight, given orally once daily. The table below provides a guide for the appropriate tablet strength and number of tablets to administer:

• Dog weight range (kg): 5.4-6.5 kg | Strength and number of tablets to be administered daily: 8.5 mg (0.5 tablet)
• Dog weight range (kg): 10.7-14.1 kg | Strength and number of tablets to be administered daily: 8.5 mg (1 tablet)
• Dog weight range (kg): 16.1-19.5 kg | Strength and number of tablets to be administered daily: 8.5 mg (1.5 tablets)

• Dog weight range (kg): 25.0-28.3 kg | Strength and number of tablets to be administered daily: 8.5 mg (2 tablets)

For dose adjustments or if you have any questions regarding administration, please consult your veterinary surgeon.

Contraindications:

• Do not use Zenrelia Tablet for Dogs 6.4mg in cases of hypersensitivity to the active substance, ilunocitinib, or to any of the excipients.
• Do not use in dogs less than 12 months of age.
• Do not use in dogs with evidence of immune suppression (e.g., hyperadrenocorticism) or with progressive neoplastic disease, as the active substance has immunomodulatory properties.
• Do not use in pregnant or lactating bitches, or in breeding animals.

Special warnings for each target species:

• Clinical signs of atopic dermatitis, such as itching and inflammation, are expected to improve within a few days of starting treatment. If there is no response within 14 days, the veterinary surgeon should re-evaluate the diagnosis and consider alternative treatments.
• It is a veterinary medicinal product for dogs only. Do not use in other species.

Special precautions for use:

• Special precautions for safe use in animals:
  The active substance has immunomodulatory properties and may potentially increase the risk of infections and exacerbate neoplastic conditions. Dogs should be monitored for the development of infections and neoplasia during treatment. Regular clinical health checks are recommended for long-term use.
• Special precautions to be taken by the person administering the veterinary medicinal product to animals:
  Wash hands immediately after administering the tablets. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the doctor. Avoid contact with skin, eyes, and mucous membranes. In case of accidental skin contact, wash the exposed area with water. In case of accidental eye contact, flush the eyes with plenty of water.

Adverse reactions:

The following adverse reactions have been observed in clinical studies:

• Common (1 to 10 animals in 100 treated animals): Diarrhoea, vomiting, lethargy, decreased appetite, skin lesions (e.g., crusts, scaling, redness), lymphadenopathy.
• Uncommon (1 to 10 animals in 1,000 treated animals): Polydipsia (increased thirst), polyuria (increased urination), weight gain, ear infections.
• Rare (1 to 10 animals in 10,000 treated animals): Decreased white blood cell count (lymphopenia, neutropenia), increased serum cholesterol, increased serum triglycerides.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

Each film-coated Zenrelia Tablet for Dogs 8.5 mg contains:

Active substance:

• 8.5 mg Ilunocitinib 

Excipients:

Tablet Core:

• Cellulose, microcrystalline 302
• Calcium hydrogen phosphate dihydrate
• Starch, pregelatinised
• Povidone K30
• Magnesium stearate

Tablet Coating:

• Opadry QX 321A220011 yellow
• Macrogol poly(vinyl alcohol) grafted copolymer (E1209)
• Talc (E553b)
• Titanium dioxide (E171)
• Glycerol monocaprylocaprate (E471)
• Poly(vinyl alcohol) (E1203)
• Iron oxide yellow (E172)
• Iron oxide red (E172)
• Iron oxide black (E172)